Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Inclusion Criteria:

1. Female patients aged 18-70 years;
2. Histopathologically confirmed HER2 positive breast cancer;
3. Patients were diagnosed with stage II-III breast cancer;
4. At least one measurable target lesion according to RECIST V1.1;
5. ECOG performance status score of 0 to 1;
6. Life expectancy ≥12 weeks;
7. Adequate bone marrow reserve and organ system function reserve;
8. Participants should be able and willing to comply with the study protocol requirement;

Exclusion Criteria:

1. Breast cancer not histologically confirmed;
2. Known inherited or acquired bleeding and thrombotic tendencies;
3. Known allergy or contraindication to the study drug and its excipients;
4. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);
5. Concurrent receipt of any other form of anti-cancer therapy;
6. History of a second primary malignancy, except for adequately treated skin cancer;
7. Participation in other drug clinical trials within 4 weeks before enrollment;
8. Major surgical procedures unrelated to breast cancer within 4 weeks prior to the first drug administration, or not fully recovered from such procedures;
9. Presence of any active autoimmune disease or history of autoimmune disease with potential for recurrence;
10. Uncontrolled or significant cardiovascular and cerebrovascular diseases;
11. Subjects with known or suspected interstitial pneumonia;
12. Presence of active hepatitis B, hepatitis C, liver cirrhosis;
13. Pregnant or lactating female patients;
14. History of definite neurological or mental disorders, or any other conditions that the investigator believes make the patient unsuitable for participating in this study.